No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 22 of the 36 quarters in the window, leaving 14 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 21.9x · 10Y median 90.6x · 26th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 37
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T16:57:19.332Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Krystal Biotech, Inc. (KRYS) stock was $326.65 as of Oct 6, 2026, 12:55 PM EDT, down 2.45% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +82.1% · 3-year avg +42.9%/yr · 5-year avg +44.3%/yr
Krystal Biotech, Inc. is a clinical-stage biotechnology company focused on developing redosable gene therapies to address severe orphan diseases across the United States.
Biotechnology · Pittsburgh, PA
Next Earnings Date
Nov 2, 2026
27 days away
EPS Estimate
1.91
Revenue Est.
$129.12M
Last Quarter Results
EPS
$1.79
vs Estimate
$1.91
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1KRYS | $9.63B | $326.64 | -2.45% | +82.10% | +44.28% | N/A | N/A |
| 2HSIC | $9.67B | $84.87 | +0.76% | +25.52% | +1.39% | +2.90% | vs KRYS |
| 3PCVX | $9.49B | $65.70 | -11.00% | +72.59% | +25.08% | N/A | vs KRYS |
| 4PODD | $9.37B | $135.32 | -0.22% | -55.95% | -13.93% | +13.11% | vs KRYS |
| 5BRKR | $9.37B | $61.53 | -3.64% | +72.96% | -3.42% | +11.49% | vs KRYS |
| 6BIO | $10.00B | $371.41 | -2.21% | +24.20% | -12.10% | +8.86% | vs KRYS |
7.09
$119.22M
vs Estimate
$120.93M
Consensus Rating
Based on 9 analysts
Average Price Target
$392.11
+20.0% upside
Low
$284.00
Current
$326.64
High
$474.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $1.71 | $1.88 | $2.09 | 7 |
| Quarter ending Dec 2026 | $1.76 | $2.07 | $2.34 | 6 |
| Quarter ending Mar 2027 | $1.90 | $2.13 | $2.64 | 2 |
| Quarter ending Jun 2027 | $1.98 | $2.22 | $2.75 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $7.10 | $7.61 | $8.19 | 9 |
| FY 2027 | $6.94 | $9.35 | $12.29 | 9 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $118.43M | $129.12M | $153.07M | 5 |
| Quarter ending Dec 2026 | $130.36M | $142.12M | $168.48M | 5 |
| Quarter ending Mar 2027 | $130.20M | $141.95M | $168.28M | 4 |
| Quarter ending Jun 2027 | $140.49M | $153.16M | $181.57M | 4 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E uses the consensus EPS estimate for the fiscal year ending Dec 31, 2026, matching Key Metrics.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $502.80M | $507.12M | $511.45M | 6 |
| FY 2027 | $656.21M | $662.07M | $667.92M | 7 |
